SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-23-008477
Filing Date
2023-01-13
Accepted
2023-01-13 17:06:01
Documents
13
Period of Report
2023-01-03
Items
Item 1.02: Termination of a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d773804d8ka.htm   iXBRL 8-K/A 53173
  Complete submission text file 0001193125-23-008477.txt   226681

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA oyst-20230103.xsd EX-101.SCH 2762
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE oyst-20230103_def.xml EX-101.DEF 14102
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE oyst-20230103_lab.xml EX-101.LAB 23871
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE oyst-20230103_pre.xml EX-101.PRE 15066
7 EXTRACTED XBRL INSTANCE DOCUMENT d773804d8ka_htm.xml XML 6487
Mailing Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 106 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Filer) CIK: 0001720725 (see all company filings)

IRS No.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39112 | Film No.: 23529470
SIC: 2836 Biological Products, (No Diagnostic Substances)